Capricor Therapeutics stock surges on FDA review extension
Capricor Therapeutics (CAPR) shares rose 29% after the FDA extended the review period for its Deramiocel BLA to November 22, 2026. The extension follows the submission of additional Phase 3 HOPE-3 data supporting a refined indication for Duchenne muscular dystrophy. The FDA accepted the amendment, citing significant unmet medical need.
How this was made
The 30-second read
Why it matters
The extension follows submission of additional Phase 3 data, suggesting the FDA sees merit but requires more review time.
Market read
CAPR stock jumped 29% on the news, highlighting the market's sensitivity to regulatory timelines in biotech.
What to watch
Potential competition from other DMD therapies and the need for reimbursement approvals.
Background
Capricor Therapeutics announced an FDA review extension for its Duchenne muscular dystrophy therapy Deramiocel.
Ticker impact
FDA extended the PDUFA target action date for Deramiocel BLA, driving a 29% share surge.
Further upside if data continue to support the refined indication.
Extension follows submission of additional Phase 3 data, reducing near‑term uncertainty.
Market effects
Positive for the DMD cell‑therapy sector as FDA shows willingness to consider refined indications.
Limited to US biotech investors; no broader regional effect.
Modest global relevance, mainly affecting biotech-focused funds.
Counterpoint
Extension may indicate lingering regulatory concerns; investors should watch for further delays.
Key entities
- companyCapricor Therapeutics
Biotech firm developing Deramiocel for DMD.
- regulatorFDA
U.S. Food and Drug Administration overseeing the BLA review.
